Pelthos Therapeutics Announces Third Quarter 2026 Financial Results

Pelthos Therapeutics reported third-quarter 2026 Zelsuvmi net product revenue of $15.2 million, up from $7.1 million a year earlier. Cost of goods sold fell 28% year over year to $1.7 million. The company had $17.7 million in cash as of September 30 and borrowed an additional $10 million from Horizon Technology Finance on October 30. Pelthos reiterated its definitive merger agreement with Castle Creek Biosciences, intended to form a diversified biotechnology company focused on pediatric and dermatological conditions.